Calprotectin as new potential clinical marker for multiple myeloma.

Autor: Khosravi P; Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran., Abroun S; Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran., Kaviani S; Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran., Masoudifar S; Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran., Farahani HS; Arak university of Medical Science, Arak, Iran.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2023 Mar 16; Vol. 18 (3), pp. e0282841. Date of Electronic Publication: 2023 Mar 16 (Print Publication: 2023).
DOI: 10.1371/journal.pone.0282841
Abstrakt: Increased levels of inflammatory cytokines in multiple myeloma (MM) patients and the role of inflammation in disease pathogenesis, have recently been considered. The aim of this study was to quantitatively evaluation of fecal calprotectin (CP) as a non-invasive biomarker for the evaluation of inflammation in patients with multiple myeloma. This study is a hospital-based case control study. MM patients referred to patients referred to medical centers of Tehran province, Iran, were identified and classified into two groups of new MM patients (n = 40) and patients undergoing treatment (n = 28). Healthy individuals were included in the study as healthy control (n = 25). Morning stool samples were collected and CP was extracted immediately. After collecting the samples, CP was measured according to ELISA method and was determined in μg/g of feces. Values ​​above 50 μg/g of feces are positive and indicate inflammation. The results revealed that there is a significant difference between groups in terms if CP mean (p = 0.001). The mean of CP among new cases, under treatment and control groups were 301.3 (SD: 141.0), 165.1 (SD: 153.9) and 36.9 (SD: 13.5), respectively. Then the groups were compared in pairs, the results showed that the new case group was significantly different from the under-treatment group (p = 0.001), and also the control group showed a significant difference with the new case group (p = 0.001) and the under-treatment group (p = 0.001) that the amount of CP in the control group was significantly lower than the other two groups. In addition, the results of the study showed a significant correlation between age and plasma cells with CP value, so that with increasing age and plasma cells, CP value also showed a significant increase. The results indicate that quantitative evaluation of CP as a non-invasive laboratory biomarker has a high potential as a clinical marker in patients with multiple myeloma and inflammation should considered as a hallmark of cancer. Further diagnostic studies are recommended.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Khosravi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje